PV-10 Treatment For Metastatic Melanoma Well-Tolerated By Patients - Evidence Of "Bystander Effect" Observed In Phase 1 Trial Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its Phase 2 melanoma study, Professor John F Thompson, MD, today presented clinical data on PV-10 at the "Perspectives in Melanoma XII" meeting at The Hague, The Netherlands.
Source: www.medicalnewstoday.comMillions Of Deaths Expected From The Burning Of Solid Fuel In Homes In China If current levels of smoking and biomass and coal fuel use in homes continues, between 2003 and 2033 there will be an estimated 65 million deaths from chronic obstructive pulmonary disease (COPD) and 18 million deaths from lung cancer in China, accounting for 19% and 5% of all deaths in that country during this period.
Source: www.medicalnewstoday.comGrants To Expand Disease-Focused Stem Cell Research Received By Einstein And Montefiore The Empire State Stem Cell Board has awarded research planning grants to Albert Einstein College of
Medicine and to Montefiore Medical Center. The grants, totaling $238,000, are part of $2 million in grants announced by State
Health Commissioner Richard F. Daines, M.D.
Source: www.medicalnewstoday.comU.S. Bans Contraceptive Supplies To British Family Planning Group Working In Africa The State Department and USAID on Thursday said they have notified six African governments to stop providing U.S.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
